Literature DB >> 2369816

In vitro studies of ciprofloxacin and survey of resistance patterns in current isolates.

C J Fernandes1, V P Ackerman.   

Abstract

We studied the activity of ciprofloxacin and other antibiotics against both routine and multiresistant (multi-R) clinical isolates. Ciprofloxacin inhibited more than 98% of most species of Enterobacteriaceae at a concentration of 2 micrograms/ml. Only Acinetobacter calcoaceticus, and to a much lesser degree, Providencia and Serratia, were resistant. Most Pseudomonas aeruginosa isolates were susceptible. Only 1% of staphylococci were resistant; the test panel included 1200 MRSA. For most species of streptococci, the MIC90 was 1 microgram/ml; for enterococci, it was 2 micrograms/ml. We also surveyed resistance in our current isolates. Resistance to ciprofloxacin has increased in A. calcoaceticus and Providencia, and in Streptococcus pneumoniae and group B streptococci. Ciprofloxacin-resistant isolates tended to show increased resistance to other antibiotics, including aminoglycosides and, later, cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2369816     DOI: 10.1016/0732-8893(90)90090-i

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  7 in total

1.  Interpretive criteria and quality control parameters for testing of susceptibilities of Haemophilus influenzae and Streptococcus pneumoniae to trimethoprim and trimethoprim-sulfamethoxazole. The Antimicrobial Susceptibility Testing OC Group.

Authors:  P C Fuchs; A L Barry; S D Brown
Journal:  J Clin Microbiol       Date:  1997-01       Impact factor: 5.948

2.  Multicenter Spanish study of ciprofloxacin susceptibility in gram-negative bacteria. The Spanish Study Group on Quinolone Resistance.

Authors:  J A García-Rodríguez; M J Fresnadillo; M I García; E García-Sánchez; J E García-Sánchez; I Trujillano
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

3.  Penetration of ciprofloxacin into the human pancreas.

Authors:  R Isenmann; H Friess; P Schlegel; K Fleischer; M W Büchler
Journal:  Infection       Date:  1994 Sep-Oct       Impact factor: 3.553

4.  High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA.

Authors:  C Janoir; V Zeller; M D Kitzis; N J Moreau; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

5.  In vitro activity of sparfloxacin compared with those of five other quinolones.

Authors:  E Cantón; J Pemán; M T Jimenez; M S Ramón; M Gobernado
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

Review 6.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

7.  Fluoroquinolone Therapy in Staphylococcus aureus Infections: Where Do We Stand?

Authors:  Neeta D Gade; Mohiuddin S Qazi
Journal:  J Lab Physicians       Date:  2013-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.